A case-control study found that the use of appetite suppressants, particularly derivatives of fenfluramine, is associated with an increased risk of primary pulmonary hypertension (PPH). The study involved 95 patients with PPH and 355 controls, and the odds ratio for any use of appetite suppressants was 6.3, with a higher risk for recent use (10.1) and prolonged use (23.1). The study also confirmed associations with other risk factors such as family history of PPH, HIV infection, cirrhosis, and use of cocaine or intravenous drugs. The study suggests that the use of appetite suppressants may contribute to the development of PPH, and active surveillance is recommended, especially as the use of these drugs is expected to increase. The study was conducted in four countries and involved a large number of medical centers. The results indicate a strong association between appetite suppressant use and PPH, with the risk increasing with the duration of use. The study also found that the risk was higher in women and that the use of these drugs was more common in patients with PPH. The study highlights the need for further research into the mechanisms by which appetite suppressants may lead to PPH and the importance of monitoring patients who use these drugs. The study also found that the risk of PPH was higher in patients with a history of HIV infection, cirrhosis, or intravenous drug use. The study concluded that the association between appetite suppressants and PPH is likely due to a causal relationship rather than bias or chance. The study also found that the risk of PPH was higher in patients who had used appetite suppressants for more than three months. The study was supported by grants from various organizations and included contributions from many researchers. The study is an important contribution to the understanding of PPH and the role of appetite suppressants in its development.A case-control study found that the use of appetite suppressants, particularly derivatives of fenfluramine, is associated with an increased risk of primary pulmonary hypertension (PPH). The study involved 95 patients with PPH and 355 controls, and the odds ratio for any use of appetite suppressants was 6.3, with a higher risk for recent use (10.1) and prolonged use (23.1). The study also confirmed associations with other risk factors such as family history of PPH, HIV infection, cirrhosis, and use of cocaine or intravenous drugs. The study suggests that the use of appetite suppressants may contribute to the development of PPH, and active surveillance is recommended, especially as the use of these drugs is expected to increase. The study was conducted in four countries and involved a large number of medical centers. The results indicate a strong association between appetite suppressant use and PPH, with the risk increasing with the duration of use. The study also found that the risk was higher in women and that the use of these drugs was more common in patients with PPH. The study highlights the need for further research into the mechanisms by which appetite suppressants may lead to PPH and the importance of monitoring patients who use these drugs. The study also found that the risk of PPH was higher in patients with a history of HIV infection, cirrhosis, or intravenous drug use. The study concluded that the association between appetite suppressants and PPH is likely due to a causal relationship rather than bias or chance. The study also found that the risk of PPH was higher in patients who had used appetite suppressants for more than three months. The study was supported by grants from various organizations and included contributions from many researchers. The study is an important contribution to the understanding of PPH and the role of appetite suppressants in its development.